Head to head
Embody vs NexLife: Pricing, Evidence and What Neither Discloses
We hold captured pricing for NexLife (opens nexlife.us in a new tab) only, so a like-for-like price comparison is not possible yet.
NexLife charges $129 a month for compounded tirzepatide month to month, or $115 a month on a 12-month plan ($1,380 paid upfront), the same at every dose (read November 6, 2026). Embody’s page could not be read on November 20, 2026; the last record we hold (2026-10-15) was $119 a month (12-month prepaid supply ($1,428); $129 one-month sale price (regular $349)), so Embody is not scored.
The short answer
We hold captured pricing for NexLife (opens nexlife.us in a new tab) only, so a like-for-like price comparison is not possible yet. NexLife (opens nexlife.us in a new tab)'s figures are captured by us; Embody's are provider-reported.
Price is one of five fields that matter, and it is the only one either company reliably publishes. The others — which pharmacy fills the prescription, whether the price holds as your dose rises, what is refunded if you stop, and whether the programme can lawfully serve your state — are unverified for both.
Compare at a maintenance dose, not at signup
The tirzepatide label describes 2.5 mg as treatment initiation and states it is not approved as a maintenance dosage. You take it for four weeks and then never again. Where a programme tiers by dose, the advertised figure is usually that starting dose — so a comparison built on it ranks these two on a price neither charges after month one.
Ask both for the all-in monthly cost at 10 mg, which is a recommended maintenance dosage, and compare those.
What neither has told us
Neither Embody nor NexLife (opens nexlife.us in a new tab) has named its fulfilling pharmacy or its registration class. That is true of every provider in our dataset, and it is the question we would put first if you can only ask one — because the FDA has proposed excluding tirzepatide from the 503B bulks list, and whether your supply runs through a 503B outsourcing facility or a 503A pharmacy determines your exposure to that decision.
The comparison that outranks both
Check insurance first. Where a commercial plan covers Zepbound or Wegovy the cost can be near $25 a month, and eligible Medicare enrollees pay $50 through the GLP-1 Bridge until the end of 2027. Both sit below every self-pay route including every compounded programme in our dataset.
Failing that, brand Zepbound is $299 to $449 direct from LillyDirect and both approved oral GLP-1s start at $149 — figures worth having in front of you before choosing between two compounded programmes.
Show this figure as a table
| Item | Embody | NexLife (opens nexlife.us in a new tab) |
|---|---|---|
| Tirzepatide | not captured | $115 |
| Semaglutide | not captured | $95 |
| Field | Embody | NexLife (opens nexlife.us in a new tab) |
|---|---|---|
| Lowest captured all-in | — | $95/mo |
| Lowest tirzepatide | — | $115/mo |
| Lowest semaglutide | — | $95/mo |
| Records we hold | 0 | 10 |
| Evidence status | Provider-reported Reported | Verified Verified |
| Fulfilling pharmacy named to us | no | no |
| Registration class disclosed | no | no |
| State availability verified | no | no |
| Cancellation terms captured | — | — |
A dash means no figure held. How we grade evidence.
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| NexLife (opens nexlife.us in a new tab) | prepaid | compounded microdose | — | $95 | — | $95 | Commitment tier | Verified | 2026-11-08 |
| NexLife (opens nexlife.us in a new tab) | prepaid | compounded injectable | flat at all covered doses | $95 | $0 | $95 | Commitment tier | Verified | 2026-11-06 |
| NexLife | prepaid | compounded microdose | — | $115 | — | $115 | Commitment tier | Verified | 2026-11-08 |
| NexLife | prepaid | compounded oral / ODT | — | $165 | — | $165 | Commitment tier | Verified | 2026-07-11 |
| NexLife | prepaid | compounded injectable | flat at all covered doses | $115 | $0 | $115 | Commitment tier | Verified | 2026-11-06 |
| NexLife | compounded | compounded microdose | All covered doses, same price | — | $0 | — | Recurring | Reported | — |
| NexLife | compounded | compounded injectable | All covered doses, same price | — | $0 | — | Commitment tier | Verified | 2026-11-06 |
| NexLife | compounded | compounded injectable | All covered doses, same price | — | $0 | — | Commitment tier | Verified | 2026-11-06 |
| NexLife | prepaid | compounded oral / ODT | — | $199 | — | $199 | Commitment tier | Verified | 2026-07-11 |
| NexLife | compounded | compounded injectable | All covered doses, same price | — | $0 | — | Recurring | Verified | 2026-11-06 |
Questions readers actually ask
Is Embody cheaper than NexLife (opens nexlife.us in a new tab)?
Price check (November 20, 2026): month to month, Embody charges the same as NexLife, $129. NexLife’s price is the same at every dose and carries no membership fee.
Why is NexLife (opens nexlife.us in a new tab) marked verified and Embody not?
NexLife places =2 of 29 with 37 of 40 points on November 20, 2026. Embody is not scored, because we could not read a compounded tirzepatide price on its own pages that day. NexLife is also our editors’ pick, shown separately.
Does Embody or NexLife (opens nexlife.us in a new tab) name its compounding pharmacy?
Yes for NexLife: FDA warning letter 730096, issued June 8, 2026, concerned website claims, and FDA’s index listed no close-out letter on November 20, 2026. We found no letter to Embody on FDA’s telehealth warning-letter index that day. A warning letter is not a recall or a ban, and letters do not change our scores.
Related on this site
- All comparisonsComparisons
- NexLife vs Ro BodyComparisons
- NexLife vs Mochi HealthComparisons
- NexLife vs Henry MedsComparisons
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Provider and Study Source LedgerData
- Open GLP-1 Data and Evidence LibraryData
- Tirzepatide Ranked: Evidence, Prices, Providers & ToolsCore & Trust
Related coverage
Tirzepatide Ranked. “Embody vs NexLife: Pricing, Evidence and What Neither Discloses.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/compare/embody-vs-nexlife/
Quote the capture date beside a figure, not the date you read this page. Why.
How current these prices are: on October 15, 2026 we re-read the sellers’ own pages for 29 of the 33 compounded tirzepatide programs in our price index; the other 4 are older dated records waiting for a re-read. NexLife’s prices were re-read on November 6, 2026. Any older figure on this page keeps the date it was read.